Short interest is probably just linked to the bot trading overnight exposure which could well be institutional shorting across multiple biotecks or whatever.
I don't really see this strategically - other - than these guys have had years to get their sh$t together really and NOW they decide to focus on the US, which was probably the winning strategy all along.
There must be strategic efficiencies as well as practical efficiencies to do this. Their products are great but they just can't get their balance sheet sorted as they seem to fail when it comes to their business plan. It's not a sexy, high profile company in Oz so always flies under the radar ... but quarterly results should change all that.
Perhaps Brian Ward wants to retire so has finally started to focus more?
Come on finish 1.60 plus, page-449
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.5¢ |
Change
0.035(6.73%) |
Mkt cap ! $189.3M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 57.0¢ | 52.0¢ | $362.9K | 680.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1700 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 5 | 1 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
54.5¢ |
Change
0.035 ( 4.81 %) |
||||
| Open | High | Low | Volume | ||
| 52.5¢ | 57.5¢ | 52.0¢ | 216572 | ||
| Last updated 15.55pm 29/05/2024 ? | |||||
| ARX (ASX) Chart |